On October 13, 2026, a Phase 3 clinical trial involving somatropin recombinant was listed as recruiting on ClinicalTrials.gov. The trial, registered under identifier NCT04867317, is titled "Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)." The study is designated Phase 3 and its current status is recruiting. The trial focuses on a veteran population diagnosed with both mild traumatic brain injury and adult growth hormone deficiency. No results have been posted for this trial as of the listed date. Somatropin recombinant remains classified as unapproved for research use in this context. This update reflects only the recruitment status and trial details as registered, without any indication of outcomes or findings. Readers interested in the study can refer to its official ClinicalTrials.gov listing for enrollment criteria and further details. For more background on somatropin recombinant, including its general research and regulatory context, see the compound overview.
Phase 3 Trial of Somatropin in Veterans With mTBI and AGHD Recruiting
See the full somatropin recombinant overview
Source: https://clinicaltrials.gov/study/NCT04867317